PHAR fundamentals
EGYPTIAN INTERNATIONAL PHARMACEUTICALS (EIPICO) financial statements, including revenue, expenses, profit, and loss
The total revenue of PHAR for the last quarter is 1.88 B EGP, and it's 25.01% higher compared to the previous quarter. The net income of Q2 24 is 175.57 M EGP.
Q3 '15
Q4 '15
Q1 '16
Q2 '16
Q3 '16
Q4 '16
Q1 '17
Q2 '17
Q3 '17
Q4 '17
Q1 '18
Q2 '18
Q3 '18
Q4 '18
Q1 '19
Q2 '19
Q3 '19
Q4 '19
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q4 '23
Q1 '24
Q2 '24
0.00
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: EGP
Q3 '15
Q4 '15
Q1 '16
Q2 '16
Q3 '16
Q4 '16
Q1 '17
Q2 '17
Q3 '17
Q4 '17
Q1 '18
Q2 '18
Q3 '18
Q4 '18
Q1 '19
Q2 '19
Q3 '19
Q4 '19
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q4 '23
Q1 '24
Q2 '24
TTM